Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Appledorn, Daniel M ^a   Dao, Kim Hien T ^c,d   O'Reilly, Sandra ^a   Maher, Veronica M ^a,b,c   McCormick, J Justin ^a,b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Center for Hematologic Malignancies Oregon Health and Science University ^*  (United States)

^c Michigan State University   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; GUANOSINE TRIPHOSPHATASE; H RAS PROTEIN; MUTANT PROTEIN; PROTEIN CDC42; RAC1 PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL HYPOXIA; CONTROLLED STUDY; FIBROBLAST CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE H RAS; PHENOTYPE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN FIBROBLAST; SOLID TUMOR; TRANSCRIPTOMICS; CELL TRANSFORMATION; DNA MICROARRAY; FIBROBLAST; GENE EXPRESSION REGULATION; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INDUCING AGENTS; CDC42 GTP-BINDING PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RAC1 GTP-BINDING PROTEIN; RAS PROTEINS; RHO GTP-BINDING PROTEINS; TETRACYCLINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77349116199     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-13     Document Type: Article

References (55)

1. Bos JL. The Ras gene family and human carcinogenesis. Mutat Res 1988, 195:255-271.
2. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989, 49:4682-4689.
3. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002, 2:133-142. 10.1038/nrc725, 12635176.
4. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81:53-62. 10.1016/0092-8674(95)90370-4, 7536630.
5. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70:389-399. 10.1016/0092-8674(92)90163-7, 1643657.
6. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992, 70:401-410. 10.1016/0092-8674(92)90164-8, 1643658.
7. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signalling networks. Genes Dev 1997, 11:2295-2322. 10.1101/gad.11.18.2295, 9308960.
8. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol Cell Biol 1997, 17:3449-3458. 232198, 9154844.
9. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995, 374:457-459. 10.1038/374457a0, 7700355.
10. Lin R, Cerione RA, Manor D. Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation. J Biol Chem 1999, 274:23633-23641. 10.1074/jbc.274.33.23633, 10438546.
11. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6:171-183. 10.1016/j.ccr.2004.07.009, 15324700.
12. Morgan TL, Yang DJ, Fry DG, Hurlin PJ, Kohler SK, Maher VM, McCormick JJ. Characteristics of an infinite life span diploid human fibroblast cell strain and a near-diploid strain arising from a clone of cells expressing a transfected v-myc oncogene. Exp Cell Res 1991, 197:125-136. 10.1016/0014-4827(91)90489-H, 1915659.
13. Hurlin PJ, Fry DG, Maher VM, McCormick JJ. Morphological transformation, focus formation, and anchorage independence induced in diploid human fibroblasts by expression of a transfected H-ras oncogene. Cancer Res 1987, 47:5752-5757.
14. Fry DG, Hurlin PJ, Maher VM, McCormick JJ. Transformation of diploid human fibroblasts by transfection with the v-sis, PDGF2/c-sis, or T24 H-ras genes. Mutat Res 1988, 199:341-351.
15. Hurlin PJ, Maher VM, McCormick JJ. Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene. Proc Natl Acad Sci USA 1989, 86:187-191. 10.1073/pnas.86.1.187, 286429, 2643097.
16. Wilson DM, Yang DJ, Dillberger JE, Dietrich SE, Maher VM, McCormick JJ. Malignant transformation of human fibroblasts by a transfected N-ras oncogene. Cancer Res 1990, 50:5587-5593.
17. Fry DG, Milam LD, Dillberger JE, Maher VM, McCormick JJ. Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras. Oncogene 1990, 5:1415-1418.
18. Jankun J, Maher VM, McCormick JJ. Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 1991, 51:1221-1226.
19. Matsuo Y, Campbell PM, Brekken RA, Sung B, Ouellette MM, Fleming JB, Aggarwal BB, Der CJ, Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signalling pathways. Mol Cancer Res 2009, 7:799-808. 10.1158/1541-7786.MCR-08-0577, 19509115.
20. Hirota K, Semenza GL. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 2001, 276:21166-21172. 10.1074/jbc.M100677200, 11283021.
21. Xue Y, Bi F, Zhang X, Zhang S, Pan Y, Liu N, Shi Y, Yao X, Zheng Y, Fan D. Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation. Int J Cancer 2006, 118:2965-2972. 10.1002/ijc.21763, 16395716.
22. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995, 15:6443-6453. 230895, 7565796.
23. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21:247-269. 10.1146/annurev.cellbio.21.020604.150721, 16212495.
24. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005, 7:533-545. 10.1016/j.ccr.2005.04.030, 15950903.
25. Sasai K, Kakumoto K, Hanafusa H, Akagi T. The Ras-MAPK pathway downregulates Caveolin-1 in rodent fibroblast but not in human fibroblasts: implications in the resistance to oncogene-mediated transformation. Oncogene 2007, 26:449-455. 10.1038/sj.onc.1209792, 16832346.
26. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. Mol Cell Biol 2000, 20:4265-4274. 10.1128/MCB.20.12.4265-4274.2000, 85794, 10825190.
27. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000, 275:26484-26491. 10.1074/jbc.M002104200, 10849421.
28. D'Orazio D, Besser D, Marksitzer R, Kunz C, Hume DA, Kiefer B, Nagamine Y. Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. Gene 1997, 201:179-187. 10.1016/S0378-1119(97)00445-9, 9409785.
29. Whitley BR, Beaulieu LM, Carter JC, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007, 104:470-479. 10.1016/j.ygyno.2006.08.048, 17070899.
30. Aguirre-Ghiso JA, Frankel P, Farias EF, Lu Z, Jiang H, Olsen A, Feig LA, de Kier Joffe EB, Foster DA. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene 1999, 18:4718-4725. 10.1038/sj.onc.1202850, 10467419.
31. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803. 10.1038/nrc909, 12360282.
32. Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998, 273:18165-18172. 10.1074/jbc.273.29.18165, 9660776.
33. Milanini-Mongiat J, Pouyssegur J, Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002, 277:20631-20639. 10.1074/jbc.M201753200, 11904305.
34. Saniger ML, Oya R, Macias D, Dominguez JN, Aranega A, Luque F. c-Jun kinase mediates expression of VEGF induced at transcriptional level by Rac1 and Cdc42Hs but not by RhoA. J Cell Biochem 2006, 98:650-660. 10.1002/jcb.20801, 16440308.
35. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005, 65:1007-1017.
36. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402. 10.1016/j.molcel.2008.04.009, 18498744.
37. Lorenzi MV, Castagnino P, Chen Q, Hori Y, Miki T. Distinct expression patterns and transforming properties of multiple isoforms of Ost, an exchange factor for RhoA and Cdc42. Oncogene 1999, 18:4742-4755. 10.1038/sj.onc.1202851, 10467422.
38. Wu WJ, Tu S, Cerione RA. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 2003, 114:715-725. 10.1016/S0092-8674(03)00688-3, 14505571.
39. Amir RE, Haecker H, Karin M, Ciechanover A. Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase. Oncogene 2004, 23:2540-2547. 10.1038/sj.onc.1207366, 14676825.
40. Tomlinson VA, Newbery HJ, Wray NR, Jackson J, Larionov A, Miller WR, Dixon JM, Abbott CM. Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 2005, 5:113. 10.1186/1471-2407-5-113, 1236916, 16156888.
41. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Ahmed N, Thornalley PJ, Sarthy VP, et al. Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. Cell 2007, 128:625. 10.1016/j.cell.2007.01.026, 17387784.
42. Tsujimoto H, Nishizuka S, Redpath JL, Stanbridge EJ. Differential gene expression in tumorigenic and nontumorigenic HeLa × normal human fibroblast hybrid cells. Mol Carcinog 1999, 26:298-304. 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M, 10569806.
43. Seo N, Tokura Y, Ishihara S, Takeoka Y, Tagawa S, Takigawa M. Disordered expression of inhibitory receptors on the NK1-type natural killer (NK) leukaemic cells from patients with hypersensitivity to mosquito bites. Clin Exp Immunol 2000, 120:413-419. 10.1046/j.1365-2249.2000.01253.x, 1905558, 10844517.
44. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103. 10.1379/CSC-99r.1, 1176476, 16038406.
45. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 2005, 41:1515-1527. 10.1016/j.ejca.2005.04.023, 15979304.
46. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23:2840-2855. 10.1200/JCO.2005.09.051, 15837998.
47. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl 3):4-10. 10.1159/000088478, 16301830.
48. Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci 2007, 44:179-201. 10.1080/10408360601040970, 17364692.
49. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 2005, 65:9294-9303. 10.1158/0008-5472.CAN-05-0993, 16230391.
50. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 2007, 67:3878-3887. 10.1158/0008-5472.CAN-06-3191, 17440102.
51. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 2006, 103:5799-5804. 10.1073/pnas.0510923103, 1458653, 16585512.
52. Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M, Fusco A. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 1998, 17:413-418. 10.1038/sj.onc.1201952, 9696033.
53. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S, Anttila S. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006, 209:206-212. 10.1002/path.1960, 16521118.
54. Zentner MD, Lin HH, Deng HT, Kim KJ, Shih HM, Ann DK. Requirement for high mobility group protein HMGI-C interaction with STAT3 inhibitor PIAS3 in repression of alpha-subunit of epithelial Na+ channel (alpha-ENaC) transcription by Ras activation in salivary epithelial cells. J Biol Chem 2001, 276:29805-29814. 10.1074/jbc.M103153200, 11390395.
55. Eynden GG, Van Laere SJ, Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006, 95:219-228. 10.1007/s10549-005-9002-1, 16244790.